DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Denmark
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
CHEMM logo

ChemoMetec A/S Stock Price

CPSE:CHEMM Community·DKK 8.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 33 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CHEMM Share Price Performance

DKK 0
-641.50 (-100.00%)
​
DKK 638.33
Fair Value
DKK 0
-641.50 (-100.00%)
​
Price DKK 0
Fri, 11 Sep 26
Fair ValueDKK 638.33
Share Pricen/a

CHEMM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value DKK 638.33 19.2% undervalued intrinsic discount

Automation Partnerships And Cell Therapy Adoption Will Support Long-Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CHEMM logo
ChemoMetec
19.2% undervalued intrinsic discount
New

Automation Partnerships And Cell Therapy Adoption Will Support Long-Term Upside Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 11 Sep
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
CHEMM logo

Automation Partnerships And Cell Therapy Adoption Will Support Long-Term Upside Potential

Fair Value: DKK 638.33 19.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

2 Risks
3 Rewards
View Full Analysis

ChemoMetec A/S Key Details

DKK 511.1m

Revenue

DKK 25.1m

Cost of Revenue

DKK 486.0m

Gross Profit

DKK 284.2m

Other Expenses

DKK 201.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Feb 03, 2027
11.73
95.10%
39.49%
0.2%
View Full Analysis

About CHEMM

Founded
1997
Employees
174
CEO
Martin Behrens
WebsiteView website
chemometec.com

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.

Recent CHEMM News & Updates

User avatar
New Narrative • Sep 11

Automation Partnerships And Cell Therapy Adoption Will Support Long-Term Upside Potential

Catalysts About ChemoMetec ChemoMetec develops and sells cell counting instruments, automation solutions and related software for Life Science customers. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates

ChemoMetec A/S Competitors

GMAB logo

Genmab

Symbol: CPSE:GMAB
Market cap: DKK 132.1b
ALK B logo

ALK-Abelló

Symbol: CPSE:ALK B
Market cap: DKK 43.1b
HLUN B logo

H. Lundbeck

Symbol: CPSE:HLUN B
Market cap: DKK 40.9b
ZEAL logo

Zealand Pharma

Symbol: CPSE:ZEAL
Market cap: DKK 18.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide